CHJT.F Stoklara Genel Bakış Bir yatırım holding şirketi olan CSPC Pharmaceutical Group Limited, Çin Halk Cumhuriyeti'nde, diğer Asya bölgelerinde, Kuzey Amerika'da, Avrupa'da ve uluslararası alanda farmasötik ürünlerin araştırılması ve geliştirilmesi, üretimi ve satışı ile ilgilenmektedir. Daha fazla detay
Ödüller Risk Analizi Tüm Risk Kontrollerini Gör Düşüncelerinizi, bağlantılarınızı ve şirket anlatımınızı yakalayın
CSPC Pharmaceutical Group Limited Rakipler Fiyat Geçmişi ve Performans
Hisse fiyatlarındaki yükseliş, düşüş ve değişimlerin özeti CSPC Pharmaceutical Group Tarihsel hisse senedi fiyatları Güncel Hisse Fiyatı HK$0.59 52 Haftanın En Yüksek Seviyesi HK$0.96 52 Haftanın En Düşük Seviyesi HK$0.54 Beta 0.64 1 Aylık Değişim -11.70% 3 Aylık Değişim -4.49% 1 Yıllık Değişim n/a 3 Yıllık Değişim -41.83% 5 Yıllık Değişim -73.11% Halka arzdan bu yana değişim 64.33%
Son Haberler & Güncellemeler CSPC Pharmaceutical Group Limited Announces SYS6005 (Antibody-Drug Conjugate) Obtains Clinical Trial Approval
CSPC Pharmaceutical Group Limited Announces Board Changes Dec 06
CSPC Pharmaceutical Group Limited to Report Nine Months, 2024 Results on Nov 15, 2024 Nov 06 CSPC Pharmaceutical Group Limited Announces Omalizumab for Injection Obtains Marketing Approval from NMPA
CSPC Pharmaceutical Group Limited Announces Valsartan Levoamlodipine Maleate Tablets Obtains Clinical Trial Approval Sep 20 CSPC Pharmaceutical Group Limited (SEHK:1093) announces an Equity Buyback for HKD 5,000 million worth of its shares. Sep 19
Daha fazla güncelleme görün CSPC Pharmaceutical Group Limited Announces SYS6005 (Antibody-Drug Conjugate) Obtains Clinical Trial Approval
CSPC Pharmaceutical Group Limited Announces Board Changes Dec 06
CSPC Pharmaceutical Group Limited to Report Nine Months, 2024 Results on Nov 15, 2024 Nov 06 CSPC Pharmaceutical Group Limited Announces Omalizumab for Injection Obtains Marketing Approval from NMPA
CSPC Pharmaceutical Group Limited Announces Valsartan Levoamlodipine Maleate Tablets Obtains Clinical Trial Approval Sep 20 CSPC Pharmaceutical Group Limited (SEHK:1093) announces an Equity Buyback for HKD 5,000 million worth of its shares. Sep 19
CSPC Pharmaceutical Group Limited Announces Aprepitant Injection Obtains Drug Registration Approval
CSPC Pharmaceutical Group Limited Declares Interim Dividend for the Six Months Ended 30 June 2024, Payable on 20 November 2024 Aug 21
CSPC Pharmaceutical Group Limited to Report First Half, 2024 Results on Aug 21, 2024 Aug 09
CSPC Pharmaceutical Group Limited Obtains Approval from the National Medical Products Administration of the People's Republic of China to Conduct Clinical Trials in China Jul 11 CSPC Pharmaceutical Group Limited Announces Enlonstobart Injection Obtains Conditional Marketing Approval
CSPC Pharmaceutical Group Limited Obtains Approval from National Medical Products Administration of the People's Republic of China to Conduct Clinical Trials in China Jun 25 CSPC Pharmaceutical Group Limited Approves Final Dividend for the Year Ended December 31, 2023
CSPC Pharmaceutical Group Limited Announces Recombinant Fully Human Anti-bKlotho Monoclonal Antibody Drug (JMT202) Obtains Approval from National Medical Products Administration of the People's Republic of China May 18
CSPC Pharmaceutical Group Limited to Report Q1, 2024 Results on May 27, 2024 May 16
Cspc Pharmaceutical Group Limited Announces That the Peramivir Injection (15Ml:0.15G) (The "Product") Developed by the Group Has Obtained Drug Registration Approval Granted by the National Medical Products Administration of the People's Republic of China, and Is Deemed to Have Passed the Consistency Evaluation of Quality and Efficacy for Generic Drugs May 15
CSPC Pharmaceutical Group Limited Proposes Final Dividend for the Year Ended 31 December 2023 Apr 28
CSPC Pharmaceutical Group Limited Announces Highly Selective Mat2A Inhibitor (SYH2039) Obtains Clinical Trial Approval in the U.S Apr 27
CSPC Pharmaceutical Group Limited Announces Dapagliflozin Tablets Obtains Drug Registration Approval Mar 23 CSPC Pharmaceutical Group Limited, Annual General Meeting, May 28, 2024
CSPC Pharmaceutical Group Limited Proposes Ordinary Final Cash Dividend for the Year Ended 31 December 2023, Payable on 26 June 2024 Mar 20
CSPC Pharmaceutical Group Limited to Report Fiscal Year 2023 Results on Mar 20, 2024 Mar 09
CSPC Pharmaceutical Group Limited's Bispecific Fusion Protein Drug JMT106 Obtains Clinical Trial Approval from the U.S. Food and Drug Administration Jan 15
CSPC Pharmaceutical Group Limited Announces Submission of New Drug Application for Irinotecan Liposome Injection to U.S. FDA Dec 18
CSPC Pharmaceutical Group Limited Obtains Approval for Dextromethorphan Hydrobromide and Quinidine Sulphate Orally Disintegrating Tablets Dec 12
CSPC Pharmaceutical Group Limited Announces Bivalent Covid-19 MRNA Vaccine (SYS6006.32) Included for Emergency Use in China Dec 02
CSPC Pharmaceutical Group Limited Obtains Approval by the National Medical Products Administration of the People's Republic of China to Conduct Clinical Trials in China Nov 29
CSPC Pharmaceutical Group Limited Obtains Approval by the National Medical Products Administration of the People's Republic of China to Conduct Clinical Trials in China Nov 28
CSPC Pharmaceutical Group Limited to Report Nine Months, 2023 Results on Nov 30, 2023 Nov 21
CSPC Pharmaceutical Group Limited's ALMB-0166 Obtains Approval by the National Medical Products Administration of the People's Republic of China to Conduct Phase II Clinical Trial Evaluating its Efficacy and Safety in Patients with Acute Ischemic Stroke in China Nov 18
Alphamab Oncology and CSPC Pharmaceutical Group Co., Ltd. Jointly Receive Breakthrough Therapy Designation on KN026 by CDE Nov 08
CSPC Pharmaceutical Group Limited Obtains Approval Granted by the National Medical Products Administration of the People's Republic of China Nov 04
CSPC Pharmaceutical Group Limited Obtains Clinical Trial Approval Oct 31
CSPC Pharmaceutical Group Limited Announces NBL-028 for the Treatment of Advanced Tumors Oct 26
CSPC Pharmaceutical Group Limited Announces Biologic License Application Approval for Narlumosbart for Injection (JMT103) by the NMPA Sep 07
CSPC Pharmaceutical Group Limited Announces Semaglutide Injection Obtains Clinical Trial Approval Aug 30
CSPC Pharmaceutical Group Limited Obtains Drug Registration Approval Granted by the National Medical Products Administration of the People's Republic of China Aug 25
CSPC Pharmaceutical Group Limited Declares Interim Dividend for the Six Months Ended 30 June 2023, Payable on 12 October 2023 Aug 24
CSPC Pharmaceutical Group Limited to Report First Half, 2023 Results on Aug 23, 2023 Aug 12
Cspc Pharmaceutical Group Limited Announces Biologic License Application of Batoclimab (Hbm9161) Jun 30
CSPC Ouyi Pharmaceutical Co., Ltd. Obtains Drug Registration Approval Granted by the National Medical Products Administration of the People's Republic of China Jun 27 CSPC Pharmaceutical Group Limited Obtains Clinical Trial Approval Granted by the National Medical Products Administration of the People's Republic of China to Conduct Clinical Trials in China
Cspc Pharmaceutical Group Limited Announces That Clinical Trial Application for Cpo301 Jun 09
Elevation Oncology Inc. Together with CSPC Pharmaceutical Group Limited Announce Promising Initial Clinical Data for SYSA1801 (EO-3021) from the Ongoing Phase 1 Dose Escalation and Expansion Study in China Jun 07
Elevation Oncology Highlights First-In-Human Phase 1 Sysa1801 (Eo-3021) Clinical Data to Be Presented by Partner Cspc Pharmaceutical Group Limited At Asco 2023 Jun 06
CSPC Pharmaceutical Group Limited Declares Final Dividend for the Year Ended 31 December 2022 Jun 01
CSPC Pharmaceutical Group Limited to Report Q1, 2023 Results on May 25, 2023 May 17
CSPC Pharmaceutical Group Limited Announces Highly Selective PRMT5 Inhibitor SYH2045 Obtains Clinical Trial Approval Jan 05
Cspc Pharmaceutical Group Limited Announces ALMB-0166 for the Treatment of Osteoarthritis Obtains Clinical Trial Approval Dec 31
CSPC Pharmaceutical Group Limited Receives Approval for SYH2043 from National Medical Products Administration of the People's Republic of China to Conduct Clinical Trials in China Dec 30
CSPC Pharmaceutical Group Limited Announces NBL-020 for the Treatment of Advanced Solid Tumors Obtains Clinical Trial Approval in the U.S Dec 23
Cspc Pharmaceutical Group Limited Announces That Syh2055 Developed by the Group Has Obtained Approval Granted by the National Medical Products Administration of the People's Republic of China to Conduct Clinical Trials in China Dec 08
CSPC Pharmaceutical Group Limited Announces Antibody-Drug Conjugate CPO204 Obtains Clinical Trial Approval in the U.S Nov 30
CSPC Pharmaceutical Group Limited's SYHX1901 Tablets Obtains Approval Granted by the National Medical Products Administration Nov 24
CSPC Pharmaceutical Group Limited Announces New Indication Application for Marketing Approval of Mingfule Nov 17
CSPC Pharmaceutical Group Limited to Report Nine Months, 2022 Results on Nov 23, 2022 Nov 12
CSPC Pharmaceutical Group Limited Appoints Li Quan as an Independent Non-Executive Director Nov 09
CSPC Pharmaceutical Group Limited Announces the Antibody-Drug Conjugate Sys6002 Oct 28
CSPC Pharmaceutical Group Limited Announces TG103 Injection Obtains Clinical Trial Approval for the Treatment of Non-Alcoholic Steatohepatitis Sep 10
CSPC Pharmaceutical Group Limited Declares Interim Dividend for the Six Months Ended 30 June 2022, Payable on 11 October 2022 Aug 25
CSPC Pharmaceutical Group Limited Announces Completion of Clinical Study of Heterologous Booster Immunization of SARS-CoV-2 mRNA Vaccine Aug 24
Cspc Pharmaceutical Group Limited Announces Selective Ntrk and Ros1 Dual Inhibitor Syhx2009 Obtains Clinical Trial Approval Aug 23
CSPC Pharmaceutical Group Limited Obtains Drug Registration Approval Granted by the National Medical Products Administration of the People's Republic of China Aug 20
Cspc Pharmaceutical Group Limited Obtains Duoenda (Mitoxantrone Hydrochloride Liposome Injection) Clinical Trial Approval for the Treatment of Neuromyelitis Optica Spectrum Disorders Aug 19
CSPC Pharmaceutical Group Limited to Report First Half, 2022 Results on Aug 24, 2022 Aug 13
CSPC Pharmaceutical Group Announces Resignation of Wu Guizhen as Independent Non-Executive Director Aug 02
CSPC Pharmaceutical Group Limited Announce Biologic License Application for Jmt103 Accepted by the NMPA Jun 23 CSPC Pharmaceutical Group Limited Announces Change of CEO
CSPC Pharmaceutical Group Limited Approves Final Dividend for the Year Ended 31 December 2021 May 27
CSPC Pharmaceutical Group Limited to Report Q1, 2022 Results on May 25, 2022 May 14 CSPC Pharmaceutical Group Limited, Annual General Meeting, May 26, 2022
CSPC Pharmaceutical Group Limited Announces COVID-19 mRNA Vaccine "SYS6006" Obtains Clinical Trial Approval Apr 04
CSPC Pharmaceutical Group Limited (SEHK:1093) acquired 51% stake in Guangzhou Recomgen Biotech Co., Ltd. Feb 09
CSPC Pharmaceutical Group Limited Announces JMT601 (CPO107) Granted Fast Track Designation by U.S. FDA for Treatment of Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Jan 28
Alphamab Oncology and CSPC Pharmaceutical Group Co., Ltd. Announce Approval of IND Application for Pivotal Clinical Study of HER2 Bispecific Antibody KN026 Combined with Chemotherapy in Gastric Cancer Jan 06
CSPC Pharmaceutical Group Limited Obtains Approval for SYHX2001 Dec 30
CSPC Pharmaceutical Group Limited Announces First Patient Dosed in the Phase 1/2 Clinical Trial of JMT601 in the U.S Dec 15
CSPC Pharmaceutical Group Limited Announces That "Sysa1801" Has Obtained Approval Granted by the National Medical Products Administration of the People's Republic of China to Conduct Clinical Trials in China Jun 17
CSPC Pharmaceutical Group Limited Obtains Approvals for SYHX1903 May 27
CSPC Pharmaceutical Group Limited announces NBL-015 Obtains Clinical Trial Approval in the U.S May 26
CSPC Pharmaceutical Group Limited Announces Innovative Drug "Syha1811 Tablets" Obtains Clinical Trial Approval in China May 21
CSPC Pharmaceutical Group Limited Approves Final Dividend for the Year Ended 31 December 2020 May 19
CSPC Pharmaceutical Group Limited Announces Dual Inhibitor Jak-Syk "Syhx1901" Obtains Clinical Trial Approval Mar 17 Cspc Pharmaceutical Group Limited Recommends a Final Dividend for the Year Ended 31 December 2020, Payable on 11 June 2021
CSPC Pharmaceutical Group Limited Announces Directorate Changes, Effective March 8, 2021 Mar 07 Hissedar Getirileri CHJT.F US Pharmaceuticals US Pazar 7D -9.0% 0.6% -0.4% 1Y n/a 10.0% 24.8%
Hissedar getirilerinin tamamını görün
Getiri vs. Endüstri: CHJT.F un US Pharmaceuticals sektörüne göre nasıl performans gösterdiğini belirlemek için yeterli veri yok.
Getiri vs Piyasa: CHJT.F un US Piyasasına göre nasıl performans gösterdiğini belirlemek için yeterli veri yok.
Fiyat Oynaklığı Is CHJT.F's price volatile compared to industry and market? CHJT.F volatility CHJT.F Average Weekly Movement n/a Pharmaceuticals Industry Average Movement 10.5% Market Average Movement 6.3% 10% most volatile stocks in US Market 17.0% 10% least volatile stocks in US Market 3.1%
İstikrarlı Hisse Senedi Fiyatı: CHJT.F hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.
Zaman İçindeki Volatilite: CHJT.F 'un son bir yıldaki oynaklık değişimini belirlemek için Yetersiz veri .
Şirket Hakkında Bir yatırım holding şirketi olan CSPC Pharmaceutical Group Limited, Çin Halk Cumhuriyeti'nde, diğer Asya bölgelerinde, Kuzey Amerika'da, Avrupa'da ve uluslararası alanda farmasötik ürünlerin araştırılması ve geliştirilmesi, üretimi ve satışı ile ilgilenmektedir. Şirket, Bitmiş İlaçlar, Dökme Ürünler ve Fonksiyonel Gıda ve Diğerleri segmentleri aracılığıyla faaliyet göstermektedir. Akut iskemik inme için NBP yumuşak kapsülleri ve enjeksiyonları; hafif ila orta dereceli hafıza ve zihinsel bozukluğu tedavi etmek için Oulaining kapsülleri ve enjeksiyonları; yetişkin idiyopatik Parkinson hastalığını tedavi etmek için Enxi; lenfoma, multipl miyelom, yumurtalık ve meme kanserleri ve diğer kötü huylu tümörler için Duomeisu; kemoterapinin neden olduğu lökopeni ve enfeksiyonu önlemek için Jinyouli ve meme kanseri için Keaili sağlar.
Daha fazla göster CSPC Pharmaceutical Group Limited Temel Bilgiler Özeti CSPC Pharmaceutical Group'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır? CHJT.F temel i̇stati̇sti̇kler Piyasa değeri US$7.17b Kazançlar(TTM ) US$706.84m Gelir(TTM ) US$4.15b
Kazanç ve Gelir En son kazanç raporundan temel karlılık istatistikleri (TTM) CHJT.F gelir tablosu (TTM ) Gelir CN¥30.27b Gelir Maliyeti CN¥8.90b Brüt Kâr CN¥21.37b Diğer Giderler CN¥16.21b Kazançlar CN¥5.16b
Temettüler
6.6% Mevcut Temettü Verimi
Şirket Analizi ve Finansal Veri Durumu Veri Son Güncelleme (UTC saati) Şirket Analizi 2024/12/25 14:03 Gün Sonu Hisse Fiyatı 2024/12/23 00:00 Kazançlar 2024/09/30 Yıllık Kazançlar 2023/12/31
Veri Kaynakları Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC 'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
Paket Veri Zaman Çerçevesi Örnek ABD Kaynağı * Şirket Finansalları 10 yıl Gelir tablosu Nakit akış tablosu Bilanço Analist Konsensüs Tahminleri +3 yıl Finansal tahminler Analist fiyat hedefleri Piyasa Fiyatları 30 yıl Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler Sahiplik 10 yıl En büyük hissedarlar İçeriden öğrenenlerin ticareti Yönetim 10 yıl Liderlik ekibi Yönetim Kurulu Önemli Gelişmeler 10 yıl
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube' da eğitimlerimiz bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.
Analist Kaynakları CSPC Pharmaceutical Group Limited 50 Bu analistlerden 27, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
Analist Kurum Wai Chak Yuen BOCI Research Ltd. Sharon Shi BOCI Research Ltd. Ethan Cui BofA Global Research
Göster 47 daha fazla analist 
